A slow-release dexamethasone implant for cancer-associated retinopathy.
Leandro J ChavesMarina L de AlbuquerqueAmanda SchnorrFrancyne Veiga Reis CyrinoMaria Lúcia HabibAndré M Vieira MessiasZélia M CorreaRodrigo JorgePublished in: Arquivos brasileiros de oftalmologia (2022)
This case report aims to show the anatomical and functional results of a patient diagnosed as having cancer-associated retinopathy treated with a controlled-release dexamethasone implant (Ozurdex). Anatomical outcomes were assessed using spectral domain optical coherence tomography; and functional outcomes, by measuring visual acuity, microperimetry, and mutifocal electroretinography. The follow-up period was 1 year.